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ABSTRACT
BACKGROUND: A variety of methods to improve skin flap survival, including
the use of pharmacologic agents, have been intensively investigated, Decreasing
neutrophil-mediated inflammation and tissue injury has been reported to be ef-
fective in improving flap survivaL Montelukast is a selective reversible cysteinyl
leukotriene receptor-1 antagonist that has been found to have protective effects
against renal ischemia reperfusion injury and burn-induced oxidative injury of the
skin in rats. However, its effects on skin flap survival have not been previously
reported.
OBJECTIVE: The aim of this study was to investigate the effects of montelukast
on neutrophil-mediated random pattern skin flap survival.
METHODS: Male Sprague-Dawley rats weighing 230 to 250 g were randomly
divided into 2 groups-the montelukast-treated group and the control group.
Caudally based rectangular random pattern skin flaps 3 x 9 em were elevated on the
backs of the rats. The flaps were sutured into their original places. In the montelukast
group, 1 mL of solution containing 10 mg/kg montelukast was administered intra-
peritoneally (IP) 30 minutes before surgery and then daily for 6 days. In the control
group, 1 mL of saline was administered IP 30 minutes before surgery and then daily
for 6 days. To observe the effects of montelukast, myeloperoxidase (MPO) activity,
an index of tissue neutrophil infiltration, was measured from extracted skin tissue
12 hours after flap elevation. Flap viability was evaluated 7 days after surgery by mea-
suring necrotic flap area and total flap area.
RESULTS: Sixteen rats (mean (SD} weight, 240.6 (6.6} g) were equally divided
between the 2 groups. All rats survived throughout the study period. Mean (SD) MPO
activity in flap tissue was significantly lower in the montelukast group than in the
control group (14.57 (2.33} vs 21.28 (4.86} D/g protein; P = 0.005). The percentage
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of necrotic flap area was significantly lower in the montelukast group than in the
control group (17.17 [7.95] vs 37.51 [l0.72]; P = 0.001).
CONCLUSION: This small, experimental, in vivo animal study found that mon-
telukast was associated with both lower MPO activity and a lower percentage of ne-
crotic random pattern skin flap area. Future studies are needed to clarify these find-
ings. (Curr Ther Res Clin Exp. 2008;69:459-465) © 2008 Excerpta Medica Inc.
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INTRODUCTION
Random pattern skin flaps are commonly used to repair various skin defects in recon-
structive surgery; however, necrosis is a major concern with these flaps. 1Although the
pathophysiology of skin flap necrosis is complex, 2 main mechanisms are suspected:
neutrophil infiltration and inadequate blood supply due to vascular thrombosis.2-6
The infiltration of polymorphonuclear leukocytes in tissue is characteristic of acute
inflammation and indicates the collective action of chemotactic mediators. The
5-lipoxygenase metabolites of arachidonic acid, various chemokines, and lipid mediators
(cysteinylleukotrienes {CysLTs]) are potent inflammatory mediators associated with
tissue injury.1-7 Reactive oxygen species, proteases, elastase, myeloperoxidase (MPO),
and various other mediators, all of which are involved in tissue injury, are released
once neutrophils migrate into the ischemic area. 5- 7 Skin blood flow initially decreases
in the distal portion of random pattern skin flaps and then increases over time. s An
incomplete ischemic state with tissue damage is found in the distal region of random
pattern skin flaps.9 Neutrophil-mediated microvascular dysfunction and tissue injury
can be reduced dramatically by preventing neutrophil influx into tissues, either by
depleting the number of circulating leukocytes or by preventing neutrophil adhesion.
In this way, the surviving flap area can be increased.!,2,9-11 MPO, which is specific to
neutrophils, is deposited in neutrophil granules.2Measurement ofMPO enzyme activity
is one of the most commonly used techniques to determine neutrophil accumulation in
tissues. 1,2,7,10 Preventing or decreasing neutrophil invasion in ischemic tissue by block-
ing any step of neutrophil activation also reduces tissue MPO enzyme activity.2
Montelukast is a selective reversible CysLTl receptor antagonist used in the treat-
ment of asthma.? It was found to reduce eosinophilic inflammation in the airways.?,12
By modifying neutrophil function, montelukast was found to provide protection
against burn-induced oxidative injury of the skin. 13
The aim of this study was to investigate the effects of montelukast on neutrophil-
mediated random pattern skin flap survival.
MATERIALS AND METHODS
This study was performed in the experimental animal laboratory of the Department
of Histology at Abant Izzet Baysal University School of Medicine (Bolu, Turkey) and
was approved by the local ethics committee of Haseki Education and Research Hos-
pital (Istanbul, Turkey).
Male Sprague-Dawley rats weighing 230 to 250 g were purchased from the experi-
mental animal production center of Di.izce University (Di.izce, Turkey). All animals
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were housed in cages at room temperature under a 12-hour day/night lighting system
and access to water and food was ad libitum. All experiments were carried out in
accordance with the World Medical Association's Declaration of Helsinki on Animal
Rights. 14
STUDY DESIGN
The animals were randomly divided into 2 groups-the montelukast-treated group
and the control group. Randomization was achieved using a computer-based number
generation technique. The montelukast group received 1 mL of solution containing
10 mg/kg montelukast intraperitoneally (IP) 30 minutes before surgery and then
daily for 6 days. In the control group, 1 mL of saline was administered IP 30 minutes
before surgery and then daily for 6 days. Rats were anesthetized using a mixture of
ketamine hydrochloride (SO mg/kg IP) and chlorpromazine (30 mg/kg IP). The sur-
geon was blinded to the treatment groups. Each animal's back was shaved with an
electric clipper. A sterile technique was used in all surgical procedures. The animals
were placed in the prone position and a 3 x 9-cm caudally based rectangular flap was
drawn on the backs of the rats according to the method described by Khouri et al. 15
After assessment of skin flap survival on postoperative day 7, all rats were euthanized
with IP injections of high-dose sodium pentothal.
SURGICAL TECHNIQUE
After the skin was shaved, each rat's back was rinsed with povidone solution. Asep-
sis was maintained by providing a local sterile environment. The caudally based dorsal
flap was located in reference to anatomic landmarks and extended from the scapular
tip to the hip joints. A dorsal random pattern flap 3 x 9 cm was elevated between
these reference points. The flap consisted of skin, panniculus carnosus muscle, and
submuscular areolar tissue. The flap was sututed back into its original location after
meticulous hemostasis.
MYELOPEROXIDASE DETERMINATION
Twelve hours2,16 after the elevation of the flap, a full-thickness 4-mm punch bi-
opsy of the skin flap was retrieved from lightly anesthetized rats at the center of each
flap by a second investigator who was blinded to treatment groups. Fifty milligrams
of flap tissue was homogenized in ice-cold 50-mM potassium phosphate buffer
(PB) (pH, 6) and centrifuged at 1O,000g for 10 minutes; pellets were suspended in
50-mM PB containing 0.5% hexadecyltrimethylammonium bromide (Sigma Chemical
Corp., St. Louis, Missouri). After 3 freezeithaw cycles, with sonication between cycles,
the samples were centrifuged at 12,000g for 10 minutes, and 0.1 mL of the super-
natant was added to 2.9 mL of 50-mM PB. Aliquots (0.3 mL) were added to 2.3 mL
of reaction mixtute containing 50-mM PB (pH, 6), o-dianisidine, and 20-mM hydro-
gen peroxide (H20 2) solution. H 20 2 was used as a substrate for MPO. Oxidized
o-dianisidine forms a stable chromophore absorption at a wavelength of 460 nm. One
unit of enzyme activity was defined as the amount of MPO present that caused a change
in absorbance measured at 460 nm for 3 minutes. One unit of MPO activity was
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defined as the amount required to degrade 1 pmol of H 20 2 per minute at 25°C. MPO
activity was recorded as activity per gram of tissue (U/g protein)Y
ASSESSMENT OF SKIN FLAP NECROSIS
The primary end point in this study was to assess skin flap necrosis. A third inves-
tigator who was blinded to the study groups assessed skin flap survival on postopera-
tive day 7. Gross observation was used to identify the line of demarcation between the
viable and the necrotic tissue. The entire flap and the necrotic and viable portions
were traced onto a transparent cellophane sheet and transferred to graph paper with a
1-mm2 grid. IS The area of necrosis was expressed as a percentage of the entire flap area
(necrotic flap percentage = necrotic flap area/total area x 100). After assessment, the
rats were euthanized using an overdose of sodium pentothal.
STATISTICAL ANALYSIS
Data were presented as mean (SD). SPSS for Windows version 11.0 (SPSS Inc.,
Chicago, Illinois) was used for statistical analysis. Because the results of the assessment
of skin flap necrosis and biochemical analyses did not distribute normally according
to the Kolmogorov-Smirnov test, they were compared using the nonparametric
Mann-Whitney V test. P < 0.05 was considered significant.
RESULTS
Sixteen rats (mean (SD} weight, 240.6 (6.6} g) were randomly divided into 2 groups-
the montelukast-treated group and the control group (received saline)-with 8 rats to
each group. All rats survived throughout the study period.
FLAP TISSUE MYELOPEROXIDASE ACTIVITY
Twelve hours after surgery, mean (SD) flap tissue MPO activity was significantly
lower in the montelukast group than in the control group (14.57 (2.33} vs 21.28
(4.86} U/g protein; P = 0.005).
FLAP SURVIVAL
On postoperative day 7, the percentage of necrotic flap area was significantly lower
in the montelukast group than in the control group (17.17 (7.95} vs 37.51 (l0.72};
P = 0.001).
DISCUSSION
In plastic surgery, random pattern skin flaps are used to reconstruct various defects. IS
Necrosis in random pattern skin flaps remains a serious problem, potentially leading
to long hospitalization and high morbidity.19 An ischemic zone that may undergo
necrosis is likely to occur in the distal portion of a random skin flap. Although many
srudies have investigated ischemic skin necrosis, the pathogenic mechanism is still
unclear. Tissue ischemia induced by leukocyte inflammation and inadequate blood
flow is believed to be the principal factor predisposing a patient to flap tissue
necrosis. 1-4
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Anti-inflammatory drugs, vasodilators, fibrinolytic enzyr 'S, energy-rich phos-
phate compounds, free radical scavengers, anticoagulants, vitamins, neutrophil func-
tion modulators, and immunosuppressants are among the most investigated pharma-
cologic agents to improve ischemic skin flap survival. 1,2,9-11,16,18,20-22 Montelukast
significantly increased skin flap survival in this experimental study. We suggest that
this finding may be related to the inhibiting effect of montelukast on neutrophil in-
filtration and its regulatory effect on generation of inflammatory mediators.
Microvascular disorders in an ischemic flap may be decreased by reducing neutro-
phil infiltration into the tissues by preventing neutrophil adhesion or decreasing cir-
culating neutrophil count.2,7,9-11 Neutrophil activation is a multistep process that
involves a complex series of events.2After a prolonged ischemic period, hypoxia causes
an elevation in cytosolic calcium concentration; phospholipase A2 and lipoxygenase
enzyme activities increase,23 resulting in increased leukotriene activity. CysLTs are
thought to be inflammatory mediators due to their potent chemotactic and chemoki-
netic properties.24 These lipid mediators have also been suggested to enhance the
vascular permeability and recruitment of neutrophils, which are associated with tissue
injury.25 CysLTs have also been reported to be produced during cerebral ischemia,
which in turn, disrupts the blood-brain barrier and leads to brain edema.26 Experi-
mental studies found that CysLT1 receptor antagonists are protective against these
effects of leukotrienes after ischemia. 27 ,28 The CysLT1 antagonist montelukast was
found to have protective effects against burn-induced oxidative injury of the skin in
rats. 13 We hypothesize that montelukast ameliorates tissue injury and flap necrosis by
blocking CysLT receptors, which are responsible for increased permeability and re-
cruitment of neutrophils and macrophages. In addition, we suggest that the decrease
in neutrophil and macrophage recruitment leads to a decrease in production of proin-
flammatory mediators. However, montelukast may act as an antioxidant in ischemic
tissues, not only by blocking the infiltration of neutrophils and macrophages, but also
by interacting with receptors expressed on mesangial cells and/or macrophages.7
However, we did not investigate this in our study. This theory should be investigated
by further srudies.
Sener et aF found that both renal tissue necrosis and tissue MPO enzyme activity
were attenuated by blocking CysLT receptors with montelukast in renal ischemia-
reperfusion in a rat model. Furthermore, skin MPO activity decreased with montelu-
kast treatment after burn-induced oxidative injury.13 MPO activity in both groups in
the present study reflected tissue neutrophil counts and was believed to be directly
related to flap tissue necrosis. Treatment with montelukast (10 mg/kg daily) 30 min-
utes before surgery and for 6 days postoperatively was associated with significantly
decreased MPO activity and flap necrosis in this srudy.
Montelukast 10 mg/d is usually used in the treatment of asthma in adults. 29 How-
ever, we used montelukast in a 10-mg/kg daily regimen, since its protective effects
against ischemia-reperfusion injury and burn-induced oxidative skin injury have been
reported at this dosage.7,13 In our opinion, lower doses may also be effective in increas-
ing skin flap survival. However, this needs to be investigated in future studies that
particularly focus on the dose-dependent properties of montelukast.
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STUDY LIMITATIONS
The method of assessing the proportion of skin flap necrosis by tracing onto a
transparent sheet and transferring onto graph paper was a limitation of this study, as
the outcome was more subjective than using a computer program to analyze a digital
picture. However, the method we used is among the methods commonly used for this
assessment. 18
CONCLUSION
In this experimental animal study, administration of montelukast was associated with
significantly decreased MPO activity, an index of tissue neutrophil recruitment, and
random pattern skin flap necrosis. Future studies are needed to clarify these
findings.
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